TransCode Therapeutics, Inc. Common Stock (RNAZ)
TransCode Therapeutics, Inc. (RNAZ) is a biotechnology company focused on developing RNA-based therapeutics for cancer and other diseases. The company utilizes innovative platforms to identify and validate RNA targets, aiming to create precision medicines that can modulate disease-driving genes. TransCode's approach involves advanced technologies such as proprietary delivery systems and genetic targeting methods to enhance the effectiveness of RNA therapeutics.
Company News
TransCode Therapeutics announced the acquisition of Polynoma LLC, a biotechnology firm focused on immuno-oncology, and received a $25 million strategic investment from CK Life Sciences. The deal includes stock issuance and will support the advancement of TransCode's microRNA-based therapeutic into Phase 2 clinical trials.
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
Can these tips help you to make money trading penny stocks? The post Successful Penny Stocks Trader Tips, 3 To Use appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Shares of TransCode Therapeutics Inc (NASDAQ: RNAZ) climbed by 65% on Thursday morning as the oncology company said in its press release that the preclinical research supporting its lead candidate, TTX-MC138, was published in Cancer Nanotechnology. CEO Michael Dudley’s remarks The preclinical study confirmed that intravenous injection of TTX-MC...